Literature DB >> 30127926

Optimized lymph node dissection range during progression of lower thoracic esophageal squamous cell carcinoma in the latest therapeutic surgical strategy: A retrospective analysis.

Hiroki Harada1, Kei Hosoda1, Hiromitsu Moriya1, Hiroaki Mieno1, Akira Ema1, Marie Washio1, Yoshimasa Kosaka1,2, Masahiko Watanabe1, Keishi Yamashita1,3.   

Abstract

The distribution of lymph node metastases, including recurrences, remains elusive in lower thoracic esophageal squamous cell carcinoma (LtESCC). The present study was a retrospective investigation into the optimized lymph node dissection range during LtESCC. Esophagectomies were performed on 163 patients with ESCC between 2009 and 2016, among whom 41 patients with LtESCC were examined. The rates of pathological and potential (including recurrences) metastases to lymph nodes and the prognosis (median, 34 months) were determined. Preoperative Docetaxel, Cisplatin and 5-fluorouracil chemotherapy was administered in >60% of cStage II/III LtESCC. During stage progression, abdominal lymph node metastasis rapidly becomes aggressive in LtESCC and lymph node metastases to the para-aortic area were more dominant than cervical and recurrent laryngeal nerve (RLN) areas. There were few control failures of regional lymph node metastases in LtESCC with surgery, if 1 unique case with cStage III who had metastases and recurrences of multiple lymph nodes during the clinical course was excluded. Defective lymph node dissection around the RLN did not worsen LtESCC prognosis with no RLN palsy. In the context of the potent preoperative chemotherapy and esophagectomy, lymph node dissection of cervical, para-aortic and RLN areas are putatively not mandatory to all LtESCC patients.

Entities:  

Keywords:  Cisplatin and 5-fluorouracil; Docetaxel; esophageal squamous cell carcinoma; lower thoracic esophageal carcinoma; lymph node metastasis; recurrent laryngeal nerve

Year:  2018        PMID: 30127926      PMCID: PMC6096102          DOI: 10.3892/ol.2018.9030

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  11 in total

1.  Three-field dissection for squamous cell carcinoma in the thoracic esophagus.

Authors:  Hiromasa Fujita; Susumu Sueyoshi; Toshiaki Tanaka; Kazuo Shirouzu
Journal:  Ann Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 1.520

2.  Characteristics and clinical significance of lymph node metastases near the recurrent laryngeal nerve from thoracic esophageal carcinoma.

Authors:  K Ye; J H Xu; Y F Sun; J A Lin; Z G Zheng
Journal:  Genet Mol Res       Date:  2014-08-25

3.  Evaluating the rational extent of dissection in radical esophagectomy for invasive carcinoma of the thoracic esophagus.

Authors:  T Nishimaki; T Suzuki; Y Tanaka; S Nakagawa; K Aizawa; K Hatakeyama
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

4.  Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.

Authors:  Keishi Yamashita; Natsuya Katada; Hiromitsu Moriya; Kei Hosoda; Hiroaki Mieno; Chikatoshi Katada; Wasaburo Koizumi; Keika Hoshi; Masahiko Watanabe
Journal:  Gen Thorac Cardiovasc Surg       Date:  2016-02-11

5.  Tumor location does not impact long-term survival in patients with operable thoracic esophageal squamous cell carcinoma in China.

Authors:  Hao-Xian Yang; Xue Hou; Qian-Wen Liu; Lan-Jun Zhang; Jin-Geng Liu; Peng Lin; Jian-Hua Fu
Journal:  Ann Thorac Surg       Date:  2012-05-01       Impact factor: 4.330

6.  Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck.

Authors:  Satoru Motoyama; Michihiko Kitamura; Reijiro Saito; Kiyotomi Maruyama; Manabu Okuyama; Jun-ichi Ogawa
Journal:  World J Surg       Date:  2006-02       Impact factor: 3.352

7.  Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.

Authors:  Keishi Yamashita; Kei Hosoda; Hiromitsu Moriya; Chikatoshi Katada; Mitsuhiro Sugawara; Hiroaki Mieno; Shoko Komori; Natsuya Katada; Masahiko Watanabe
Journal:  Oncology       Date:  2017-01-21       Impact factor: 2.935

8.  Indications for abdominal para-aortic lymph node dissection in patients with esophageal squamous cell carcinoma.

Authors:  Yutaka Shimada; Masayuki Imamura; Fumiaki Sato; Masato Maeda; Jun-Ichi Kaganoi; Yosuke Hashimoto; Takatsugu Kan; Shiro Nagatani; Zhigang Li
Journal:  Surgery       Date:  2002-07       Impact factor: 3.982

9.  Improved survival for patients with upper and/or middle mediastinal lymph node metastasis of squamous cell carcinoma of the lower thoracic esophagus treated with 3-field dissection.

Authors:  Hiroyasu Igaki; Yuji Tachimori; Hoichi Kato
Journal:  Ann Surg       Date:  2004-04       Impact factor: 12.969

10.  Comprehensive Registry of Esophageal Cancer in Japan, 2010.

Authors:  Yuji Tachimori; Soji Ozawa; Hodaka Numasaki; Ryu Ishihara; Hisahiro Matsubara; Kei Muro; Tsuneo Oyama; Yasushi Toh; Harushi Udagawa; Takashi Uno
Journal:  Esophagus       Date:  2017-05-19       Impact factor: 4.230

View more
  2 in total

1.  Patient selection for salvage surgery after definitive chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Hiroki Harada; Keishi Yamashita; Chikatoshi Katada; Hiromichi Ishiyama; Takafumi Soeno; Marie Washio; Mikiko Sakuraya; Hideki Ushiku; Masahiro Niihara; Kei Hosoda; Naoki Hiki
Journal:  Langenbecks Arch Surg       Date:  2020-07-15       Impact factor: 3.445

2.  Extent and consequences of lymphadenectomy in oesophageal cancer surgery: case vignette survey.

Authors:  Didi Jjm de Gouw; Mirre Scholte; Suzanne S Gisbertz; Bas P L Wijnhoven; Maroeska M Rovers; Bastiaan R Klarenbeek; Camiel Rosman
Journal:  BMJ Surg Interv Health Technol       Date:  2020-04-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.